Literature DB >> 29303374

Most important barriers and facilitators of HTA usage in decision-making in Europe.

K L Cheung1,2,3, S M A A Evers1, H De Vries2, P Levy4, S Pokhrel5, T Jones5, M Danner6, J Wentlandt6, L Knufinke6, S Mayer3, M Hiligsmann1.   

Abstract

BACKGROUND: To enhance usage of health technology assessment (HTA) in decision-making, it is important to prioritise important barriers and facilitators to the uptake of HTA. This study aims to quantify and compare the relative importance of barriers and facilitators regarding the use of HTA in several European countries.
METHODS: A survey containing two best-worst scaling (BWS) object case studies (i.e. barriers and facilitators) were conducted among 136 policy makers and HTA researchers from the Netherlands, Germany, France, and United Kingdom. Hierarchical Bayes analysis generated the mean relative importance score (RIS) for each factor and subgroup analyses assessed differences between countries.
RESULTS: Six barriers (RIS≥5) and five facilitators (RIS≥6) were deemed highly important. Eleven barriers and ten facilitators differed in their importance between countries. Policy characteristics, research & researcher characteristics, and organisation & resources were particularly important to facilitate uptake of HTA, such as an explicit framework for decision-making and research of sufficient quality.
CONCLUSION: The most paramount barriers and facilitators to HTA usage were quantified. For all countries it is crucial to create an explicit framework for the decision-making context to include HTA evidence. Country differences in the quality of research emphasize the need for enhanced international collaboration in HTA.

Keywords:  Europe; barriers; best-worst; facilitators; health technology assessment

Mesh:

Year:  2018        PMID: 29303374     DOI: 10.1080/14737167.2018.1421459

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  4 in total

1.  HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2020-02

2.  MUW researcher of the month.

Authors:  Susanne Mayer
Journal:  Wien Klin Wochenschr       Date:  2018-11       Impact factor: 1.704

Review 3.  Harmonization issues in unit costing of service use for multi-country, multi-sectoral health economic evaluations: a scoping review.

Authors:  Claudia Fischer; Susanne Mayer; Nataša Perić; Judit Simon
Journal:  Health Econ Rev       Date:  2022-08-03

Review 4.  Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries.

Authors:  Abdulaziz Ibrahim Alzarea; Yusra Habib Khan; Abdullah Salah Alanazi; Muhammad Hammad Butt; Ziyad Saeed Almalki; Abdullah K AlAhmari; Saud Alsahali; Tauqeer Hussain Mallhi
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.